Chronic Pelvic Pain: Suppressing the Cycle or Treating the Nerve
A woman with confirmed endometriosis has pelvic pain that hormonal suppression hasn't fully resolved, raising a real, uncomfortable possibility — that her pain may no longer be driven only by the disease the hormones are meant to control.
L.F., a 31-year-old woman, was diagnosed with endometriosis four years ago via laparoscopy after nearly a decade of pain her earlier providers had repeatedly attributed to "bad periods," a delay she describes with real, still-present frustration. Surgical excision at diagnosis provided meaningful relief for about a year, and she has been on a progestin-based hormonal regimen since, which controlled her pain reasonably well for the first two years. Over the past eight months, though, the pain has crept back — not identical to her original presentation, she says, but persistent in a way that doesn't track her cycle the way her earlier pain clearly did, present most days regardless of where she is in her hormonal regimen. She works as a physical therapist, a job requiring her to be on her feet most of the day, and has started quietly building in extra breaks she hasn't told her employer the real reason for.
The straightforward reading — that a lower-intensity hormonal regimen has simply become insufficient to control ongoing endometriosis activity — is a real, guideline-consistent possibility; ACOG's own practice guidance on endometriosis-associated pelvic pain treats hormonal suppression as the pharmacologic mainstay, and escalating within that class, from a progestin to a GnRH agonist, before concluding hormonal therapy has failed altogether is a standard, defensible next step. What complicates a simple escalation, though, is the specific character of what has changed: pain that no longer tracks her hormonal cycle the way her original endometriosis pain clearly did is a real, recognized signal in the chronic pelvic pain literature — long-duration pelvic pain is well documented to develop a central sensitization component that can persist and even generate its own symptoms independent of ongoing disease activity, meaning her described shift from cyclical to near-constant pain may itself be diagnostic information rather than simply a sign the hormones need to work harder. Which explanation is actually driving her current symptoms — under-suppressed disease, or a sensitization process layered on top of it — is not something either position can settle by assumption alone.
Gynecology-pain co-consult
Her endometriosis is confirmed, surgically documented, and hormonal suppression is the guideline-endorsed mainstay of treatment per ACOG. A progestin that controlled her pain well for two years and is now only partially working is a real reason to escalate within that same class — moving to a GnRH agonist — before concluding hormonal therapy itself has failed her.
I'd add gabapentin directly rather than escalate hormones further. What she's describing — pain that no longer tracks her hormonal cycle, present most days regardless of where she is in her regimen — is a real, recognized pattern in chronic pelvic pain. Long-duration pelvic pain frequently develops a central sensitization component that persists independent of ongoing disease activity. A pattern shift like hers is a meaningful clinical signal, not just a sign the hormones need to work harder.
Escalating hormonal suppression assumes the mechanism hasn't changed — but the character of her pain has changed, and that shift is exactly what a sensitization process would look like.
You're both offering real, mechanistically coherent explanations, and I don't think we have to choose between them on assumption. A focused pain-mapping history — asking her directly whether her current pain still has any cyclical component left, or whether it's genuinely constant and untethered from her hormonal pattern — is a concrete, low-cost step that could meaningfully distinguish under-suppressed disease from a sensitization process before either drug class gets escalated. We haven't actually asked her that yet today.
Choosing between escalating hormones and adding gabapentin right now would be treating this as a coin flip between two real possibilities when a fairly simple diagnostic question could narrow it considerably first.
Agreed: a structured pain-mapping history taken during the same visit, with the treatment decision — GnRH agonist escalation versus gabapentin addition — made contingent on what that history revealed rather than decided in advance. Both the gynecologist and pain medicine specialist accepted deferring their own opening positions to the pharmacologist's diagnostic step, rather than splitting the difference by starting both drugs simultaneously.
The history, taken that same visit, found her pain had become genuinely constant with no remaining cyclical pattern she could identify — evidence favoring the sensitization-driven explanation. Gabapentin was started; hormonal escalation was deferred, not ruled out, with an explicit plan to revisit it if gabapentin doesn't produce meaningful improvement, since a negative response wouldn't fully rule out an under-suppressed disease component still contributing underneath the sensitization pattern.